ALLY BRIDGE GROUP NY LLC
Q2 2023 Form 13-F

NEW YORK, NEW YORK
CIK 0001822947 · CRD 291072 · SEC-registered investment adviser
Consolidated report · includes 1 manager since Q1 2021
$82.6M Reported Value Total

ALLY BRIDGE GROUP (NY) LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $146,724,487, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
3 funds · $340.7M gross asset value
Hedge Fund: $340.7M
Source: Form ADV filed 2026-03-31
Reported value
$82.6M
Quarter over quarter
+8.3%
Holdings
17
Top-10 concentration
82.9%

Filing Structure

Reports holdings for

  • Yu Fan · File #028-20833 · since Q1 2021 · declared by one filing
  • Fan Yu (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing

Key People

Form ADV owners & control persons
Fan Yu
SHAREHOLDER AND DIRECTOR
Slanix Paul T Alex
PRESIDENT & PORTFOLIO MANAGER
Michael Novick Bendetson
COO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2023 13F record

Q2 2023 13F filing summary

Q2 2023 Form 13F portfolio summary
Period of report June 30, 2023
Filed August 14, 2023
Form 13F-HR
Reported value $82.6M
Positions 17
Change in reported value +8.2%
New positions 8
Exited positions 9
Position turnover 65.4%
Top-10 concentration 82.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
14 $76.0M
Q2 2026 13F
Filed Aug 14, 2026
23 $113.1M
Q1 2026 13F
Filed May 18, 2026
21 $123.8M
Q4 2025 13F
Filed Feb 17, 2026
13 $96.0M
Q3 2025 13F
Filed Nov 14, 2025
18 $164.2M
Q2 2025 13F
Filed Aug 14, 2025
24 $120.2M
Q1 2025 13F
Filed May 15, 2025
28 $110.9M
Q4 2024 13F
Filed Feb 14, 2025
30 $116.6M
Q3 2024 13F
Filed Nov 14, 2024
29 $186.8M
Q2 2024 13F
Filed Aug 14, 2024
25 $167.9M
Q1 2024 13F
Filed May 15, 2024
22 $179.9M
Q4 2023 13F
Filed Feb 14, 2024
22 $167.8M
Q3 2023 13F
Filed Nov 14, 2023
19 $85.2M
Q2 2023 13F
Filed Aug 14, 2023
17 $82.6M
Q1 2023 13F
Filed May 15, 2023
18 $76.3M
Q4 2022 13F
Filed Feb 14, 2023
30 $102.8M
Q3 2022 13F
Filed Nov 14, 2022
39 $151.5M
Q2 2022 13F
Filed Aug 15, 2022
22 $109.7M
Q1 2022 13F
Filed May 16, 2022
21 $134.9M
Q4 2021 13F
Filed Feb 14, 2022
30 $286.1M

4 earlier quarters on file — choose one from the quarter menu above.

Top 17 holdings · Q2 2023

Largest Q2 2023 13F positions by reported value
# Holding Reported value % of portfolio
1 RETA REATA PHARMACEUTICALS INC-A $10.8M 13.04%
2 VRNA VERONA PHARMA PLC - ADR $10.3M 12.49%
3 XENE XENON PHARMACEUTICALS INC $10.3M 12.45%
4 CYTK CYTOKINETICS INC $7.3M 8.83%
5 GERN GERON CORP $6.8M 8.25%
6 MRUS MERUS NV $5.2M 6.35%
7 VRDN VIRIDIAN THERAPEUTICS INC $4.8M 5.81%
8 MLTX MOONLAKE IMMUNOTHERAPEUTICS $4.7M 5.65%
9 MRNS MARINUS PHARMACEUTICALS INC $4.2M 5.14%
10 BDTX BLACK DIAMOND THERAPEUTICS I $4.0M 4.89%
11 PRAX PRAXIS PRECISION MEDICINES I $3.7M 4.46%
12 JSPR JASPER THERAPEUTICS INC $3.4M 4.18%
13 CMPX COMPASS THERAPEUTICS INC $2.9M 3.52%
14 MDVL MEDAVAIL HOLDINGS INC $1.4M 1.75%
15 MDXH MDXHEALTH SA-ADR $1.2M 1.44%
16 CNTX CONTEXT THERAPEUTICS INC $1.0M 1.27%
17 RPID RAPID MICRO BIOSYSTEMS INC-A $403.3K 0.49%

Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings